Jubilant Therapeutics is preparing to begin Phase II and first-in-human trials later in 2023 with two Orphan Drug Designations, an advantageous safety profile, and enhanced therapeutic indices. The company's pipeline uses their Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine to identify candidate molecules with improved therapeutic indices and the ability to penetrate the brain for pharmacologically active concentrations. Their lead program, JBI-802, is an oral inhibitor of coREST that targets hematological tumors like essential thrombocythemia (ET), certain neuroendocrine tumors, and resistance to immune-checkpoint inhibition.
The second clinical-stage drug candidate is JBI-778, a third-generation protein arginine methyltransferase 5 (PRMT5) inhibitor that targets tumors with mutations in spliceosome proteins present in about 10% of lung tumors.
Jubilant's approach to drug discovery has made it a core strength. They aim to develop candidates through clinical proof of concept before partnering those assets with companies that have the expertise to advance them through late-stage clinical development and market them.